Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBT Margin (2020 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed EBT Margin for 6 consecutive years, with 5.0% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 7689.0% year-over-year to 5.0%, compared with a TTM value of 16.61% through Sep 2025, down 1471.0%, and an annual FY2024 reading of 0.15%, up 7535.0% over the prior year.
  • EBT Margin was 5.0% for Q3 2025 at Fennec Pharmaceuticals, up from 32.69% in the prior quarter.
  • Across five years, EBT Margin topped out at 43522.22% in Q2 2021 and bottomed at 8056.86% in Q3 2021.
  • Average EBT Margin over 5 years is 2778.0%, with a median of 26.89% recorded in 2023.
  • The sharpest move saw EBT Margin plummeted -655361bps in 2023, then soared 40619bps in 2024.
  • Year by year, EBT Margin stood at 8056.86% in 2021, then surged by 109bps to 754.38% in 2022, then tumbled by -104bps to 26.89% in 2023, then grew by 30bps to 18.94% in 2024, then skyrocketed by 74bps to 5.0% in 2025.
  • Business Quant data shows EBT Margin for FENC at 5.0% in Q3 2025, 32.69% in Q2 2025, and 13.3% in Q1 2025.